TORONTO, June 25, 2018 /CNW/ - HLS Therapeutics Inc.
("HLS" or the "Company") (TSXV: HLS) announces voting results for
the election of directors at its Annual Meeting of Shareholders
held on June 22, 2018 in Toronto, Ontario.
A total of 22,700,718 Common Shares, or 82.76% of the total
Common Shares issued and outstanding, were voted in connection with
the meeting. Based on proxies received prior to the meeting and
votes cast in person at the meeting, each director nominee was
elected by a substantial majority as follows:
|
Nominees
|
Votes
For
|
%
For
|
Votes
Withheld
|
%
Withheld
|
|
William
Wells
|
22,406,001
|
99.95%
|
11,431
|
0.05%
|
|
Greg
Gubitz
|
22,405,998
|
99.95%
|
11,434
|
0.05%
|
|
J. Spencer
Lanthier
|
22,399,613
|
99.92%
|
17,819
|
0.08%
|
|
Yvon
Bastien
|
22,400,444
|
99.92%
|
16,988
|
0.08%
|
|
Rodney
Hill
|
22,400,679
|
99.93%
|
16,753
|
0.07%
|
|
Don
DeGolyer
|
22,400,274
|
99.92%
|
17,158
|
0.08%
|
|
Daniel
Tasse
|
22,400,679
|
99.93%
|
16,753
|
0.07%
|
Shareholders also voted in favour of the Company's stock option
incentive plan and the appointment of Ernst & Young LLP as its
auditors.
About HLS Therapeutics Inc.
HLS (TSXV: HLS) is a specialty pharmaceutical company focused on
the acquisition and commercialization of late-stage development,
commercial-stage promoted and established, branded pharmaceutical
products in the North American markets. HLS's focus is on products
targeting the central nervous system and cardiovascular therapeutic
areas. HLS's management team is comprised of seasoned
pharmaceutical executives with a strong track record of success in
these therapeutic areas and at managing products in each of these
lifecycle stages.
Neither the TSX Venture Exchange nor its regulation services
provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE HLS Therapeutics Inc.